NA
TRIB

NewEdge Advisors’s Trinity Biotech TRIB Stock Holding History

NewEdge Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$3 – 4376
2025
Q3 		$3 Hold
3
– – ﹤0.01% 4087
2025
Q2 		$2 Sell
3
-3
-50% -$2 ﹤0.01% 3978
2025
Q1 		$3 Hold
6
– – ﹤0.01% 3934
2024
Q4 		$5 Buy
+6
New +$8 ﹤0.01% 3879

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's TRIB Position: Q4 2025 in Review

NewEdge Advisors sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 3 shares — an estimated $3 sold.

NewEdge Advisors first reported a position in TRIB in Q4 2024 and held it in 4 quarters. The position peaked at $5 in Q4 2024. 27 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • NewEdge Advisors reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 3 Trinity Biotech shares in Q4 2025, an estimated $3.
  • NewEdge Advisors first reported a position in Trinity Biotech in Q4 2024 and held it in 4 quarters.
  • NewEdge Advisors's Trinity Biotech position peaked at $5 in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.